Dianabol vs Erythropoietin (EPO)
Well Studied vs Extensively Studied
monitor Mechanism-based · 51% Both Dianabol and Erythropoietin (EPO) can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Dianabol Erythropoietin (EPO)
Weight 300.44 Da 30,400 Da
Half-life ~4-6 hours 4-12 hours (IV), ~25 hours (SubQ)
Chain — 165 amino acids
Type 17-alpha-alkylated anabolic steroid (C20H28O2) Glycoprotein hormone
Key Benefits
Dianabol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Significant strength gains within the first 1-2 weeks
03 Enhanced nitrogen retention and protein synthesis
04 Improved glycogenolysis and muscular endurance
05 Pronounced muscle fullness and pumps from increased intracellular water and glycogen
06 Effective oral kickstart while waiting for injectable compounds to saturate
07 One of the fastest-acting anabolic compounds available
Erythropoietin (EPO)
01 Stimulates red blood cell production
02 Increases oxygen-carrying capacity
03 FDA-approved for anemia treatment
04 Improves endurance capacity
05 Supports patients with chronic kidney disease
06 Helps chemotherapy-induced anemia
07 Well-characterized mechanism of action
08 Extensively studied safety profile
Dosing Protocols
Dianabol
20-50 mg/day / Split doses throughout the day
Erythropoietin (EPO)
50-300 IU/kg based on medical indication / 1-3 times weekly depending on response
CKD Anemia (medical) 50-100 IU/kg 3x weekly
Chemotherapy Anemia (medical) 150-300 IU/kg 3x weekly
Maintenance (medical) Individualized 1-3x weekly
Side Effects
Dianabol
Significant water retention and bloating (estrogen-mediated)
Elevated blood pressure from fluid retention and increased red blood cell mass
Liver stress with elevated ALT/AST enzymes (dose and duration dependent)
Back pumps (painful lower back cramping during exercise)
Increased appetite
Oily skin and acne
Suppression of endogenous testosterone production (HPTA suppression)
Mild mood changes (increased aggression, irritability, or euphoria)
Erythropoietin (EPO)
Injection site reactions
Headache
Hypertension
Joint pain
Flu-like symptoms
Contraindications
Pre-existing liver disease or impaired hepatic function
Active or history of hormone-sensitive cancers (prostate, breast)
Uncontrolled hypertension or significant cardiovascular disease
Elevated hematocrit (above 54%) at baseline
Concurrent use of other hepatotoxic oral steroids (do not stack C17-aa orals)
Pregnancy or potential exposure to pregnant women
Heavy alcohol use (compounded hepatotoxicity risk)
Cholestatic liver conditions or history of drug-induced liver injury
Uncontrolled hypertension
Pure red cell aplasia history
Hemoglobin >12 g/dL (increased cardiovascular risk)
Active malignancy (relative contraindication)
Research Evidence
Dianabol Erythropoietin (EPO)
Status Well Studied Extensively Studied
References 5 studies 4 studies
Latest 2017 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.